Healthcare Industry News: radiosurgery
News Release - August 4, 2016
New Data Show InCise(TM) Multileaf Collimator for the CyberKnife(R) M6(TM) System may Expand Patient Population Eligible for Precise Radiation TreatmentsSUNNYVALE, Calif., Aug. 4, 2016 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (ARAY) announced today that more than 45 studies on the use of the CyberKnife® System were presented during poster and oral sessions at the 58th Annual Meeting of the American Association of Physicists in Medicine (AAPM) held in Washington, DC, July 31 – August 4, 2016. The CyberKnife System is the only stereotactic body radiation therapy (SBRT) system capable of tracking and automatically correcting for target motion in real time, even while the tumor moves. The System's sub-millimeter accuracy enables clinicians to effectively treat tumors while preserving healthy tissue.
Since its introduction in 2015, clinicians have been using the InCise™ Multileaf Collimator (MLC) with the CyberKnife System to deliver full-body radiosurgery faster. According to the most recent MD Buyline Market Intelligence Briefing™, CyberKnife System users "highly recommend" the MLC noting "it makes the treatment time much more efficient." Ongoing research, including seven abstracts presented at this year's AAPM meeting, reinforces market interest in the multileaf collimator as clinicians continue to explore the benefits it provides to their patients and their practice. Research highlights include:
Studies reinforce the efficacy and reliability of the InCise MLC for the CyberKnife M6™ System in expanded patient populations.
- A study conducted at Mercy Health Grand Rapids evaluated whether use of the InCise MLC with the CyberKnife M6 System can expand the types of clinical cases treated by delivering external beam radiotherapy using conventional fractionation, in addition to the SRS and SBRT plans for which the system is known. The tumor sites planned were pancreas, head and neck, prostate, anal, and esophagus, with target average diameter ranging from 7 cm to 13 cm. Results indicate that the CyberKnife System, with the InCise MLC, can achieve acceptable dose distributions in large volume tumors treated with conventional dose and fractionation, and provides satisfactory healthy tissue sparing.
- Researchers at Stanford University Cancer Center evaluated the InCise™ 2 MLC overall performance for one month after commissioning. The physics assessment found that all measurements were within Accuray Incorporated specifications. The Incise 2 MLC for CyberKnife M6 proved to be accurate and reliable, and is currently in clinical use at the cancer center.
For information on the CyberKnife System, visit http://www.accuray.com/solutions/treatment-delivery/cyberknife-treatment-delivery
About the CyberKnife® System
The CyberKnife® M6™ Series enables precise, high-quality, dose distributions to be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The CyberKnife System is the only robotic full-body radiosurgery system available today.
Important Safety Information
For Important Safety Information please refer to http://www.accuray.com/safety-statement-radiation-treatment
Accuray Incorporated (ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient outcomes, adoption of Accuray's technologies and Accuray's leadership position in radiation oncology innovation and technologies. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including but not limited to the risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K, filed on August 28, 2015, the company's reports on Form 10-Q, filed on November 5, 2015 and February 1, 2016 and April 29, 2016, and the company's other filings with the SEC.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAccuray Launches Synchrony(R) Motion Tracking and Correction Technology for the Radixact(R) System
Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer
Accuray and China Isotope and Radiation Corporation Enter Joint Venture Contract to Manufacture and Sell Radiation Oncology Systems in China